

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/00, C07K 14/00, 7/50</b>		A1	(11) International Publication Number: <b>WO 96/27385</b>  (43) International Publication Date: 12 September 1996 (12.09.96)
<p>(21) International Application Number: <b>PCT/US96/02932</b></p> <p>(22) International Filing Date: 1 March 1996 (01.03.96)</p> <p>(30) Priority Data: 08/398,021 3 March 1995 (03.03.95) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/398,021 (CIP) Filed on 3 March 1995 (03.03.95)</p> <p>(71) Applicant (<i>for all designated States except US</i>): <b>ELI LILLY AND COMPANY [US/US]</b>; Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): <b>BECKER, Gerald, W. [US/US]</b>; 13877 Priscilla Place, Fishers, IN 46038 (US). <b>HALE, John, E. [US/US]</b>; 7644 Forest Drive, Fishers, IN 46038 (US). <b>MACKELLAR, Warren, C. [US/US]</b>; 7956 Edgewood Court, Plainfield, IN 46168 (US).</p> <p>(74) Agents: <b>CALTRIDER, Steven, P. et al.</b>; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</p>			
<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i></p>			

(54) Title: ANTI-OBESEITY PROTEINS

(57) Abstract

The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

**BEST AVAILABLE COPY**